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Abstract
The roles of the Notch pathway proteins in normal adult vascular physiology and the pathogenesis of brain arteriovenous malformations are
not well-understood. Notch 1 and 4 have been detected in human and mutant mice vascular malformations respectively. Although mutations
in the human Notch 3 gene caused a genetic form of vascular stroke and dementia, its role in arteriovenous malformations development has
been unknown. In this study, we performed immunohistochemistry screening on tissue microarrays containing eight surgically resected
human brain arteriovenous malformations and 10 control surgical epilepsy samples. The tissue microarrays were evaluated for Notch 1–4
expression. We have found that compared to normal brain vascular tissue Notch-3 was dramatically increased in brain arteriovenous malfor-
mations. Similarly, Notch 4 labelling was also increased in vascular malformations and was confirmed by western blot analysis. Notch 2 was
not detectable in any of the human vessels analysed. Using both immunohistochemistry on microarrays and western blot analysis, we have
found that Notch-1 expression was detectable in control vessels, and discovered a significant decrease of Notch 1 expression in vascular
malformations. We have demonstrated that Notch 3 and 4, and not Notch 1, were highly increased in human arteriovenous malformations.
Our findings suggested that Notch 4, and more importantly, Notch 3, may play a role in the development and pathobiology of human arterio-
venous malformations.
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Introduction
Brain arteriovenous malformations (BAVM) are abnormal vascular
structures caused by the replacement of normal capillary beds with
enlarged and tangled vessels. The lesions are thought to be congeni-
tal in origin, and the overwhelming majority of cases are sporadic.
These rare lesions can lead to increased blood flow and high pressure
in the vessels that can lead to the dilation of feeder arteries and veins.
This dilation weakens the vessels making them susceptible to haem-
orrhage [1].
Brain arteriovenous malformations are often asymptomatic, but
symptomatic patients present with headaches, seizures and haemor-
rhage, potentially leading to potential significant neurological impair-
ment or death. Current treatment modalities, including surgery,
endovascular embolization, and/or radiosurgery carry significant
risks. Treatment associated risk of morbidity (9%) and mortality (3%)
may even outweigh the risk of rupture itself [1]. Additionally, some
lesions are deemed non-treatable due to their size or location [2].
Therefore, the development of alternative treatment strategies with
lower morbidities is of paramount interest. Little is known about the
underlying biology of BAVMs. The primary factors regulating vessel
hierarchy were originally thought to be hemodynamic forces [3]. It is
now known that genetic signalling contributes to vascular hierarchy,
and the Notch pathway has emerged as the critical mediator for the
differentiation of arteries and veins [4].
The Notch pathway controls cell fate and influences proliferation,
differentiation, and apoptosis during development. Mammalian Notch
has four receptor isoforms Notch 1–4 and its mammalian ligands
Delta and Serrate [5]. Loss of Notch function often leads to reduction
of blood vessel diameter, whereas gain of notch function leads to dila-
tion. Notch signaling can also regulate arteriovenous differentiation
during embryogenesis, and its role is intertwined with that of the
VEGF A pathway [6, 7].
The proposed role for Notch signalling in the pathogenesis of vas-
cular malformations was based on abnormalities that resulted from
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Notch pathway mutations in animal models of vasculogenesis. It has
been demonstrated that ephrine B2, a transmembrane ligand, marked
arteries but not veins, and the Eph-B4, the ephrine B2 receptor,
marked veins and not arteries [4]. Notch signalling deficient zebrafish
have been shown to lose their expression of Eph B2, where Eph B4,
normally associated with veins, was ectopically expressed [8]. It has
been suggested that Notch signalling was required for proper devel-
opment of arterial and venous blood vessels and that the major role
of Notch signalling was to repress venous differentiation within devel-
oping arteries [8]. Changes in arteriovenous gene expression profiles
of model animals were accompanied by an arteriovenous shunt, a
hallmark of BAVMs, between the dorsal aorta and posterior cardinal
vein [9].
In mutant mice, endothelial cells, with constitutively active Notch-
4, have led to an AVM phenotype and developed cerebral arteriove-
nous shunting and vessel enlargement by 3 weeks of age. Surpris-
ingly, these malformations were reversible if Notch-4 transgene
expression was repressed by doxycycline, demonstrating that the
involvement of Notch signalling was not only sufficient to induce but
also required to sustain the disease [10].
Notch-1 signalling was found in smooth muscle and endothelial
cells of human BAVMs but not in normal control vessels. In addition,
Notch-1 ligands, such as Jagged-1 and Delta-like 4 and the down-
stream effector Hes-1, were also in abundance in human BAVMs
[11].
Notch-3 receptors play a key role in the function and survival of
vascular smooth muscle cells [12, 13]. These receptors are thought
to be essential for the maintenance of healthy muscle cells in the
brain’s arteries. This receptor protein is located on the surface of the
muscle cells that surround blood vessels that are specific to arteries.
Mutations in other genes of the Notch-3 signalling pathway have been
implicated in diseases such as Alagille syndrome, which is caused by
a micro deletion of the 20p12 gene, corresponding to the ligand JAG
1. Cerebral autosomal-dominant arteriopathy with subcortical infarcts
and leukoencephalopathy is caused by mutations in the Notch-3 gene
itself [14].
Although the Notch signalling pathway seems to play a critical role
in arteriovenous cell fate determination during vascular development,
its function in normal adult vascular physiology and in the pathogene-
sis of AVMs in humans is still not clearly understood. In this study
using tissue microarrays (TMAs), we evaluated the expression of
Notch receptor proteins (1–4) in human brain AVMs as compared to




Tissue sections, mainly from the white matter, from an 18 patient retro-
spective cohort that contains eight patients with BAVM resections and
10 control patients with temporal lobe epilepsy, were processed and
analysed in this study. A TMA was created from both BAVM and control
tissue that was analysed for Notch receptor proteins. A hollow needle
was used to remove tissue cores from regions containing blood vessels
in the paraffin embedded human samples. Two to four different regions
were taken from each BAVM and control sample which were included in
the TMA screening for this study. These tissue cores were then inserted
in a recipient paraffin block in a precisely spaced array pattern and cut
using a Leica RM2235 rotary microtome (Rankin Biomedical Corp.,
Holly, MI, USA). The TMAs allowed the entire retrospective cohort to be
labelled all at once on one single slide. Therefore, all reagent concentra-
tions, temperatures and times were identical for all samples screened
(control/BAVM). The patients ranged in age from 2 to 66 years old with
a mean age of 42.2 years. All studies involving patients were conducted
under protocols approved by the Institutional Review Board at Geisinger
Health System.
Tissue staining
Haematoxylin and Eosin staining (Symphony system; Ventana Medical
Systems, Inc., Tucson, AZ, USA) was performed on the formalin fixed
TMA sections to identify general vessel features and structures. Ver-
hoeff Van Gieson Elastin Stain Kit (Polysciences Inc., Warrington, PA,
USA) was used on the paraffin embedded TMA sections to identify
arteries in the samples analysed. CD31 antibody (cat#131M15; Dako,
Carpinteria, CA, USA) was used to verify the endothelial cells (data not
shown).
Immunohistochemistry
Immunohistochemical labelling for Notch 1–4 was performed on forma-
lin fixed and paraffin embedded 5 lm TMA sections, according to previ-
ously published methods [15]. Immunoreactivity was scored based on
the observed labelling in the vessels: Negative (); < 10% (+/); 25%
(+), 50% (++); > 50% (+++).
Slides containing tissue arrays were subjected to heat-induced epi-
tope retrieval (HIER) using either a citrate buffer (pH 6) or EDTA (pH
9). HIER was carried out at 98°C for 20 min. followed by 20 min. of
cooling in the same buffer.
Double label immunohistochemistry for the Notch proteins (1, 3, 4)
and elastin antibody was accomplished using the EnVision G/2 Double-
stain System for Rabbit and/or Mouse (Dako). Since Notch 2 was not
detectable in any of our samples, we did not double label using the
Notch 2 antibody. The double labelling procedure followed these steps:
Dual Endogenous Enzyme Block (5 min.), rabbit anti-Notch 1 (1:200),
Notch-3 (1:200), or Notch-4 (1:1000) primary antibodies (45 min.; Ab-
cam, Cambridge, MA, USA), HRP Polymer (15 min.), DAB+ chromogen
(3 min.); Doublestain Block (3 min.), elastin primary antibody
(35 min.), Rabbit/Mouse LINK (10 min.), AP Polymer (15 min.), Perma-
nent Red chromogen (5–6 min.). The tissue arrays were counterstained
with Gill 2 Haematoxylin, dehydrated and coverslipped using Permount
mounting media (Electron Microscopy Sciences, Hatfield, PA, USA).
Western blotting
Fresh white matter tissue samples from four BAVMs and three control
epilepsy surgical resections where processed and used for performing
western blot analysis for the purposes of verifying our TMA findings.
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50% Percoll/50% Minimum Essential Media (MEM; Gibco/Invitrogen,
Grand Island, NY, USA) was prepared in a 5 ml tube. The Percoll/Mem
mix was spun at 39,200 9 g for 1 hr at 4°C. The BAVM tissue was
minced and placed in a homogenizer with 4 ml MEM using a mortar
and pestle. 2 ml of the homogenized tissue was carefully layered on top
of the Percoll gradient and spun at 1700 9 g at 4°C for 10 min. The
upper and lower layers of the gradient were removed, and the middle
layer containing the enriched endothelial cells was collected, and
washed with media. It was then centrifuged in an Eppendorf 5415 rotor
at 9300 9 g for 1 min. at 4°C. The supernatant was discarded, and the
pellet was re-suspended in 19 RIPA buffer (Sigma-Aldrich, St. Louis,
MO, USA) with a complete protease inhibitor tablet (Roche, Mannheim,
Germany) added. The supernatant was sonicated for 5 sec. and frozen
at 80°C for Westerns. Protein concentrations were determined using a
Pierce Protein assay kit (Thermo Fisher Scientific Inc., Rockford, IL,
USA). 20 lg of protein were loaded for each sample on a 4–12% gradi-
ent Novex Criterion gel (Invitrogen, Carlsbad, CA, USA). The gels were
run at 200 volts for 1½ hrs. The gel was then transferred onto an Im-
mobilion P membrane (Millipore, Billerica, MA, USA) for 1½ hrs at
100 volts, blocked with blotto (Thermo Fisher Scientific Inc.), followed
by the primary rabbit anti-Notch 1 (ab8925; 80 kDa), rabbit anti-Notch
3 (ab23426; 244 kDa) or rabbit anti-Notch 4 antibody (ab33163;
543 kDa) overnight. Notch 1–4 antibodies were against the cleaved
form of the protein (1:500; 1:1000, 1:100; Abcam). Secondary antibody
goat anti-rabbit horseradish peroxidase (Jackson Immunochemicals,
West Grove, PA, USA) was added for 1 hr at room temperature. Immu-
noreactive proteins were detected with Super Signal Western chemilu-
minescence (Thermo Fisher Scientific, Inc.) substrate and developed on
x-ray film (Blue 5 9 7) (Midsci, St. Louis, MO, USA).
Results
To screen the levels of Notch 1–4 proteins in human BAVMs and con-
trol vessels, we performed immunohistochemistry using specific
Notch antibodies on a TMA to simultaneously allow labelling and
analyses of the entire retrospective cohort. An elastin antibody, as
well as a specific elastin stain was used to identify arteries in the tis-
sue samples. Haematoxylin and eosin stain was used to look at the
general histology of the vessels analysed in the TMA. Normal artery
vessel wall structure could be seen using haematoxylin and eosin
staining in blood vessels removed from control epilepsy brains




Fig. 1 Haematoxylin and Eosin staining of
control (A and C) and AVM blood vessels
(B and D). Elastin Antibody labelling in
control (E) and AVM tissue (F). Arrows
show areas of elastin antibody labelling.
2009 (A and B), 4009 (C–F).
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lamina (IEL) labelled intensely with an elastin antibody (Fig. 1E,
arrow). This layer bordered the inner Tunica Intima containing the
flattened endothelial cells. Tunica Media layer contained primarily
smooth muscle cells and the Tunica Adventitia layer containing con-
nective tissue.
The BAVM tissue had abnormal artery wall structure when stained
with haematoxylin and eosin (Fig. 1B and D). We could not identify a
consistently defined IEL with the elastin antibody in the BAVM sam-
ples (Fig. 1F; arrow). The layers appeared disruptive, and the pattern
of elastin staining was abnormal (Fig. 1F).
The Notch 1 antibody that was used in this study recognized the
cleaved intracellular form of Notch 1. When this antibody was used
on control and BAVM on our TMA, we found that the overall Notch 1
labelling had decreased in the internal artery vessel walls from a score
of approximately 25% (+)in control vessels to a score of approxi-
mately <10% (+/) label in the BAVM vessels (Table 1). We identi-
fied that Notch 1 (Fig. 2) was expressed most intensely on the IEL of
the vessel wall in control arteries (Fig. 2A and C; see arrows). The
labelling appeared to be in the same layer as the elastin antibody
labelling from Figure 1E. An arrow head indicates a blood vessel
where there was minimal Notch 1 labelling (Fig. 2C). We identified a
few of these throughout the tissue but overwhelmingly the vessels
were highly Notch 1 positive in the control samples.
Notch 1 labelling in the BAVM vessels was dramatically decreased
and almost absent in the IEL of the vessel wall (Fig. 2B and D; see
arrows). Because of the lack of staining, it was hard to identify the
IEL in some of the vessel walls in BAVM tissue. This was similar to
the decrease in the elastin antibody labelling of the IEL from Fig-
ure 1F. Western blot analysis for Notch 1, on the endothelial cell
enriched percoll gradient layer, demonstrated a significant 1.5-fold
decrease (***P = 0.0007) in the Notch 1 protein in BAVMs as com-
pared to control protein levels (Fig. 3), supporting the TMA findings
for Notch 1.
Notch 2 did not appear to label vessels in either control or BAVM
tissue that we analysed (Table 1).
Overall, Notch 4 had an increase in staining in the BAVM vessels
and surrounding tissue (Fig. 4B and D) when compared to control
epilepsy vessels (Fig. 4A and C). We found that the overall labelling
intensity did vary among the different BAVM patients analysed. How-
ever, age was not a factor with the samples that we analysed. We
Table 1 Summary of results on patient vessels labelled with Notch 1-4
DX Age Gender Notch 1 Notch 2 Notch 3 Notch 4
AVM 24 F + +/ ++ ++
AVM 27 F +  +++ ++
AVM 40 M   + +/
AVM 61 M + + +++ +++
AVM 44 F +/  + +/
AVM 42 M +  +++ ++
AVM 2 M   +++ +/
AVM 66 M   + 
Control 39 F +  + +
Control 51 M +/  + +/
Control 49 F + + + +
Control 37 F +/  + +/
Control 29 M +  + +
Control 57 F ++  + +
Control 38 M ++  + +
Control 35 M +  + +
Control 53 M +  + +
Control 66 M ++  + +
Negative (); Minimal staining <10% (+/); 25% (+), 50% (++); > 50% (+++).
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found a score anywhere from <10% (+/) to >50% (+++) for Notch
4 labelling, whereas, control arteries generally had the same intensity
score of 25% (+) (Table 1). Notch 4 labelled the IEL of the blood ves-
sel walls in control vessels (Fig. 4A and C). It also appeared to label
the endothelial cell layer (Fig. 4C). When Notch 4 was combined with
elastin staining (pink stain), we confirmed that a portion of Notch 4
was associated with the elastin positive IEL of the artery wall (Fig. 4E;
see arrow). The majority of the increase in Notch 4 labelling in BAVMs
appeared to be due to a diffuse labelling throughout the disrupted
vascular tissue (Fig. 4B and D). The Notch 4 antibody could be
detected on many structures throughout the vessel wall (Fig. 4F). The
elastin antibody labelling also appeared disrupted (Fig. 4F; arrow)
similar to the pattern seen with the elastin stain in Figure 1F. Western
blot analysis for Notch 4 revealed a significant 4.8-fold increase
(**P = 0.003) in total Notch 4 protein in the BAVM samples as com-
pared to controls (Fig. 5).
Notch 3, on the other hand, had the most dramatic increase in
overall labelling in the BAVM vessel walls. We found vessels in the
control tissue that had a score of about 25% (+), whereas in the AVM
vessels, we found that most vessels had >50% (+++) labelling
(Table 1). Notch 3 antibody labelled the IEL and throughout the
smooth muscle cell layer of the artery wall (Fig. 6A and C), and the
intensity of labelling as well as the extent of labelling increased dra-
matically in BAVM vessels (Fig. 6B and D; arrows). The vessels were
highly disorganized, and the Notch 3 labelling appeared dramatically
increased in both the IEL and the smooth muscle cell layer (Fig. 6B
and D). We were unable to perform a reliable Western blot on Notch 3
because of the high molecular weight of this receptor, and therefore
the inconsistency of running and transferring of this protein. When
Notch 3 labelling was combined with elastin staining on control ves-
sels, the Notch 3 receptor labelling could be identified in the elastin
A B
C D
Fig. 2 Immunohistochemistry for Notch 1
in control (A and C). Arrows indicate
Notch 1 present in the interior wall of the
blood vessels of the control sections.
Arrow head indicates a blood vessel with
minimal Notch 1 labelling. BAVM TMA
samples (B and D). Arrows indicate ves-
sels with decrease Notch 1 labelling in
BAVMs. 2009 (A and B), 4009 (C and
D).
Fig. 3Western Blot for Notch 1 in control (C1–3) and AVM (A1–3) fresh
surgical samples. Multiple bands could be identified between 76–
150 MW. The bracket indicates the bands that were included in the
quantification. Bar graphs represent Total Density after they were nor-
malized with the B-actin internal control antibody. Graphs were made
using Graph Pad Prism 5 Software, ***P = 0.0007.
1990 ª 2015 The Authors.
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positive IEL and the smooth muscle cell tunica media layer of the
arteries (Fig. 6E; see arrow head). This labelling pattern was com-
pletely disrupted in the AVM arteries. The elastin protein appeared to
label the connective tissue in the Tunica Adventitia surrounding the
IEL and can also be seen in the smooth muscle layer of the Tunica
Media where Notch 3 is highly expressed in the BAVMs (Fig. 6F; see
arrow).
Discussion
In this study, we found that the overall structural integrity of the arter-
ies in the BAVMs were very disrupted. The pattern of elastin labelling
also appeared abnormal in the BAVMs. We found that the active form
of Notch-3 was normally present in the IEL and smooth muscle layer
of cerebral blood vessel arteries and increased dramatically in five of
eight human BAVMs that we analysed. Notch 4 was present on con-
trol arteries and increased in half of the TMA BAVM arteries that were
analysed. The labelling of Notch 4 had a more diffuse pattern of stain-
ing in the BAVMS compared to the other Notch proteins. By western




Fig. 4 Immunohistochemistry for Notch 4
protein in control (A and C) and co-
labelled with elastin (E). Arrow indicates
the elastin staining in the IEL of the blood
vessel shown. Immunohistochemistry for
Notch 4 protein in BAVM tissue (B and D)
and co-labelled with elastin (F). Arrow
head indicates elastin staining. 2009 (A
and B), 4009 (C–F).
Fig. 5Western Blot for Notch 4 protein in AVM (A1–4) and control
(C1–3) fresh surgical samples. A single band at molecular weight 53
could be detected for Notch 4. Bar graphs represent Total Density after
they were normalized with the B-actin internal control antibody. Graphs
were made using Graph Pad Prism 5 Software, **P = 0.0030.
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4 protein in BAVMs over controls. This was not surprising since
previously ZhuGe et al. showed that Notch 4 expression increased
on the vessel wall of human BAVMs [16]. However, our results
revealed that Notch 4 was not as robust as Notch 3 expression in
human BAVMS. The diffuse pattern of Notch 4 labelling that we see
is possibly a result of the abnormal architect of the vessel wall and
tissue, as well as, some non-specific labelling due to the structural
defects of the tissue.
We found that Notch 2 protein was not detectable in both control
and BAVM vessels. This was supported by the fact that Notch 2
expression has never been identified on vascular cells [17].
Unlike ZhuGe et al., that suggested that Notch 1 was not detect-
able in control vessels, but had increased in AVMs [11], we found that
Notch 1 was detectable on control human brain arteries. There were a
few vessels in the TMA with low Notch 1 labelling, but that was more
of an exception than a rule. Our western findings verified that BAVMs
had a significant decrease in Notch 1 labelling compared to control
vessels. Although ZhuGe et al., did use a similar Notch 1 antibody in
some of their labelling experiments [11], we performed all of our
immunohistochemistry labelling on TMAs that gave us the advantage
of labelling all of our samples simultaneously. We believe that TMAs
along with our supported findings by western blot make a strong
argument that Notch 1 labelling in the vessels of BAVMs are signifi-
cantly reduced overall in the IEL of arteries. We could not determine if
Notch 1 expression was reduced because of a decrease in the number
of endothelial cells in the IEL of BAVMs or if the cells themselves
make less Notch 1 protein. Future studies addressing this issue
should be performed.
Together, our findings suggest that some of the Notch proteins
may be involved at some stage in the development of BAVMs. There-
fore, it could serve as a potential target for development of treatment
strategy. Except for surgical resection, endovascular embolization or
radiosurgery, there are no other established treatments for BAVMs.




Fig. 6 Immunohistochemistry for Notch 3
in control epilepsy (A and C) and co-
labelled with elastin (E). BAVM tissue (B
and D) and co-labelled with elastin (F).
Arrows indicate Notch 3 labelling on blood
vessel walls. Arrow head indicates elastin
staining in the IEL of control vessels.
2009 (A and B), 4009 (C–F).
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to a substantial subgroup of patients because of excessive treatment
risks. Nearly 20% of BAVM patients are left without adequate treat-
ment options.
Even with these findings, we cannot say with certainty if the Notch
pathway is the key factor in the development of BAVMs. BAVMs could
develop independently from the Notch pathway, and hemodynamic
stress caused by high flow arteriovenous shunting may be secondar-
ily activated including the Notch pathway. We know that BAVMs are
dynamic lesions with potential for growth, regression and anatomical
changes. Even if we cannot interfere with the development of congen-
ital BAVMs, one possible aim for treatment might be to reduce the
growth rate or help in the regression of the BAVMs.
The Notch signalling pathway is activated through direct cell-cell
interaction with bindings between the Notch ligands in the signalling
cells and the receptors on the responding cell. Importance of this sig-
nalling is demonstrated by the fact that targeted disruption of Notch
ligands in mice results in embryonic lethality with vascular agenesis.
It has also been shown that vascular malformations in Notch 4 over-
expressing transgenic mice are reversible if expression of an acti-
vated Notch 4 transgene is repressed [10].
Considering previous investigations of the role of Notch pathway
in BAVMs, our findings suggest that aberrant Notch 3 signalling, in
human brain BAVMs, may have a role in the pathogenesis of BAVM.
This could open up new potential therapeutic targets for the treatment
of BAVMs. Future studies are essential to determine which Notch
pathway genes are differently expressed (up-regulated or down-regu-
lated) in BAVMs as compared to normal brain vessel and to determine
whether the aberrant phenotype can be reduced by changing the
expression of the altered gene.
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